Company Encyclopedia
View More
name
ImmunoPrecise Antibodies
IPA.US
ImmunoPrecise Antibodies Ltd. operates as an AI-driven biotherapeutic research, technology, and scientifically robust life science company. It discovers and develops customized and novel antibodies by generating proprietary and patented processes, procedures, and innovative approaches to antibody discovery, development, and production. The company was incorporated in 1983 and is headquartered in Austin, Texas.
746.92 B
IPA.USMarket value -Rank by Market Cap -/-

Financial Score

20/11/2025 Update
D
Life Sciences Tools and ServicesIndustry
Industry Ranking60/61
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-101.96%E
    • Profit Margin-123.30%E
    • Gross Margin55.25%B
  • Growth ScoreD
    • Revenue YoY-3.40%D
    • Net Profit YoY-11.82%D
    • Total Assets YoY-26.85%E
    • Net Assets YoY-34.62%E
  • Cash ScoreD
    • Cash Flow Margin-81.10%D
    • OCF YoY-3.40%D
  • Operating ScoreC
    • Turnover0.47C
  • Debt ScoreC
    • Gearing Ratio46.84%C

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    ImmunoPrecise Antibodies (IPA) to Release Quarterly Earnings on Monday

    ImmunoPrecise Antibodies (NASDAQ:IPA) is set to release its Q1 2026 earnings on September 15, with analysts predicting a loss of $0.04 per share and revenue of $5.90 million. The company previously reported a loss of $0.04 EPS and revenue of $5.06 million for the last quarter. Currently, ImmunoPrecise has a market cap of $96.68 million and a price-to-earnings ratio of -3.08. Analysts maintain a "Buy" rating with an average target price of $4.00. Institutional investors hold 6.70% of the company's stock.

    Market Beat·
    US
    IPA
    0.00%
    Market Beat·
    US
    IPA
    0.00%

    ImmunoPrecise evolves into MindWalk to reflect AI-focused future

    ImmunoPrecise Antibodies has rebranded as MindWalk to emphasize its focus on artificial intelligence. The change follows the sale of a subsidiary for $12 million and aims to position the company as a bio-native AI platform. CEO Jennifer Bath highlighted the company's mission to uncover hidden patterns in biology to improve medicine. MindWalk has also changed its stock ticker from "IPA" to "HYFT," reflecting its technology's role in drug discovery. The company reported a net loss of $30.2 million over the past year but raised $11.7 million from the sale of its Dutch unit.

    Fiercepharma·
    US
    HYFT
    +2.84%
    US
    IPA
    0.00%
    Fiercepharma·
    US
    HYFT
    +2.84%
    US
    IPA
    0.00%

    ImmunoPrecise Rebrands as MindWalk, Changes NASDAQ Ticker to "HYFT

    ImmunoPrecise Antibodies Ltd. has rebranded as MindWalk, reflecting its transition to a Bio-Native AI platform. This change emphasizes the integration of AI, multi-omics data, and advanced laboratory research. The company's Nasdaq ticker symbol has also changed to "HYFT."

    Reuters·
    US
    IPA
    0.00%
    US
    HYFT
    +2.84%
    Reuters·
    US
    IPA
    0.00%
    US
    HYFT
    +2.84%

    Theravance Biopharma Inc. to Participate in H.C. Wainwright 27th Annual Global Investment Conference in New York City

    Theravance Biopharma Inc. will participate in the H.C. Wainwright 27th Annual Global Investment Conference in New York City. CEO Rick Winningham will engage in a Fireside Chat on September 9, 2025, at 1:30 PM EDT. The company's management will also hold in-person meetings, and a live webcast will be available for interested parties.

    Reuters·
    US
    TBPH
    -4.11%
    Reuters·
    US
    TBPH
    -4.11%

    ImmunoPrecise Antibodies Ltd. Advances Universal Dengue Vaccine Initiative to Preclinical Manufacturing Stage

    ImmunoPrecise Antibodies Ltd. has advanced its universal dengue vaccine initiative to the preclinical manufacturing stage, focusing on in vivo testing and virus neutralization analysis. This follows the validation of a conserved dengue epitope using their LENSai™ platform and HYFT® technology. The vaccine candidate will be tested using proprietary immunization protocols at their Canadian facility, with results pending. This marks a significant step in their translational development efforts across infectious diseases.

    Reuters·
    US
    IPA
    0.00%
    US
    HYFT
    +2.84%
    Reuters·
    US
    IPA
    0.00%
    US
    HYFT
    +2.84%